FTO was associated with GBM when it was reported that the FDA-approved FTO-inhibitor meclofenamic acid (MA2) suppressed the proliferation of GSCs across five different glioblastoma-derived cell lines, and that MA2 administration in mice suppressed xenograft GBM tumour growth. This evidence concerns the gene FTO and glioblastoma.